Cite
HARVARD Citation
Sahebjam, S. et al. (n.d.). 287 Safety and antitumor activity of indoleamine 2, 3-dioxygenase 1 (IDO-1) inhibitor KHK2455 in combination with anti-CCR4 monoclonal antibody mogamulizumab in patients with advanced solid tumors. Journal for immunotherapy of cancer. pp. A175-A176. [Online].